Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome

Natalie Neale, Concepcion Padilla, Luciana Mascarenhas Fonseca, Tony Holland, Shahid Zaman, Natalie Neale, Concepcion Padilla, Luciana Mascarenhas Fonseca, Tony Holland, Shahid Zaman

Abstract

People with Down syndrome (DS) develop Alzheimer's disease (AD) at higher rates and a younger age of onset compared to the general population. As the average lifespan of people with DS is increasing, AD is becoming an important health concern in this group. Neuroimaging is becoming an increasingly useful tool in understanding the pathogenesis of dementia development in relation to clinical symptoms. Furthermore, neuroimaging has the potential to play a role in AD diagnosis and monitoring of therapeutics. This review describes major recent findings from in vivo neuroimaging studies analysing DS and AD via ligand-based positron emission tomography (PET), [18F] fluorodeoxyglucose (FDG)-PET, structural magnetic resonance imaging (sMRI), and diffusion tensor imaging (DTI). Electroencephalography (EEG) and retinal imaging are also discussed as emerging modalities. The review is organized by neuroimaging method and assesses the relationship between cognitive decline and neuroimaging changes. We find that amyloid accumulation seen on PET occurs prior to dementia onset, possibly as a precursor to the atrophy and white matter changes seen in MRI studies. Future PET studies relating tau distribution to clinical symptoms will provide further insight into the role this protein plays in dementia development. Brain activity changes demonstrated by EEG and metabolic changes seen via FDG-PET may also follow predictable patterns that can help track dementia progression. Finally, newer approaches such as retinal imaging will hopefully overcome some of the limitations of neuroimaging and allow for detection of dementia at an earlier stage.

Keywords: AD, Alzheimer's disease; APP, amyloid precursor protein; Aβ, amyloid beta; Biomarkers; DS, Down syndrome; DTI, diffusion tensor imaging; Dementia; Diffusion tensor imaging (DTI); EEG, electroencephalography; Electroencephalography (EEG); FDG, fluordexoyglucose; Magnetic resonance imaging (MRI); NFT, neurofibrillary tangles; PET, positron emission tomography; Positron emission tomography (PET); sMRI, structural magnetic resonance imaging.

References

    1. Annus T., Wilson L.R., Hong Y.T., Acosta-Cabronero J., Fryer T.D., Cardenas-Blanco A.…Holland A.J. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2016;12(5):538–545.
    1. Annus T., Wilson L.R., Acosta-Cabronero J., Cardenas-Blanco A., Hong Y.T., Fryer T.D.…Nestor P.J. The Down syndrome brain in the presence and absence of fibrillar β-amyloidosis. Neurobiol. Aging. 2017;53:11–19.
    1. Antonarakis S.E., Lyle R., Dermitzakis E.T., Reymond A., Deutsch S. Chromosome 21 and Down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 2004;5(10):725–738.
    1. Babiloni C., Albertini G., Onorati P., Muratori C., Buffo P., Condoluci C.…Rossini P.M. Cortical sources of EEG rhythms are abnormal in Down syndrome. Clin. Neurophysiol. 2010;121(8):1205–1212.
    1. Beacher F., Daly E., Simmons A., Prasher V., Morris R., Robinson C.…Murphy D.G.M. Alzheimer's disease and Down's syndrome: an in vivo MRI study. Psychol. Med. 2009;39(4):675–684.
    1. Beacher F., Daly E., Simmons A., Prasher V., Morris R., Robinson C.…Murphy D.G.M. Brain anatomy and ageing in non-demented adults with Down's syndrome: an in vivo MRI study. Psychol. Med. 2010;40(4):611–619.
    1. Berisha F., Feke G.T., Trempe C.L., McMeel J.W., Schepens C.L. Retinal abnormalities in early Alzheimer's disease. Invest. Ophthalmol. Vis. Sci. 2007;48(5):2285–2289.
    1. Bookheimer S.Y., Strojwas M.H., Cohen M.S., Saunders A.M., Pericak-Vance M.A., Mazziotta J.C., Small G.W. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 2000;343(7):450.
    1. Bouman A., Hennekam R. Advances in molecular genetics. In: Newton Richard W., Puri Shiela, Marder Liz., editors. Down Syndrome: Current Perspectives. Mac Keith Press; 2015.
    1. Brier M.R., Gordon B., Friedrichsen K., McCarthy J., Stern A., Christensen J.…Ances B.M. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci. Transl. Med. 2016;8(338) 338ra66-338ra66.
    1. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., Yankner B.A. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron. 2002;33(5):677–688.
    1. Cairns N.J., Ikonomovic M.D., Benzinger T., Storandt M., Fagan A.M., Shah A.R.…Morris J.C. Absence of Pittsburgh compound B detection of cerebral amyloid Β in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch. Neurol. 2009;66(12):1557–1562.
    1. Caraci F., Iulita M.F., Pentz R., Aguilar L.F., Orciani C., Barone C.…Cuello A.C. Searching for new pharmalogical targets for the treatment of Alzheimers disease in Down syndrome. Eur. J. Pharmacol. 2017
    1. Castro P., Zaman S., Holland A. Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments. J. Neurol. 2016;264(4):804–813.
    1. Cohen A.D., Rabinovici G.D., Mathis C.A., Jagust W.J., Klunk W.E., Ikonomovic M.D. Using Pittsburgh compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv. Pharmacol. 2012;64:27–81.
    1. Cole J.H., Annus T., Wilson L.R., Remtulla R., Hong Y.T., Fryer T.D.…Holland A.J. Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline. Neurobiol. Aging. 2017;56:41–49.
    1. De Felice F.G., Wu D., Lambert M.P., Fernandez S.J., Velasco P.T., Lacor P.N.…Klein W.L. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging. 2008;29(9):1334–1347.
    1. Fenoll R., Pujol J., Esteba-Castillo S., de Sola S., Ribas-Vidal N., García-Alba J.…de la Torre R. Anomalous white matter structure and the effect of age in Down syndrome patients. J. Alzheimers Dis. 2017;57(1):61–70.
    1. Fonseca L.M., Yokomizo J.E., Bottino C.M., Fuentes D. Frontal lobe degeneration in adults with Down syndrome and Alzheimer's disease: a review. Dement. Geriatr. Cogn. Disord. 2016;41(3–4):123–136.
    1. Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., Gajdusek D.C. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer’s disease. Science (New York, N.Y.) 1987;235(4791):877–880.
    1. Golla S.S.V., Timmers T., Ossenkoppele R., Groot C., Verfaillie S., Scheltens P.…Yaqub M. Quantification of tau load using [18F]AV1451 PET. Mol. Imaging Biol. 2017:1–9.
    1. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (New York, N.Y.) 2001;293(5534):1491–1495.
    1. Haier R.J., Head K., Head E., Lott I.T. Neuro-imaging of individuals with Down syndrome at-risk for dementia: evidence for possible compensatory events. NeuroImage. 2008;39(3):1324.
    1. Handen B.L., Cohen A.D., Channamalappa U., Bulova P., Cannon S.A., Cohen W.I.…Klunk W.E. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement. 2012;8(6) 496.
    1. Hartley S.L., Handen B.L., Devenny D.A., Hardison R., Mihaila I., Price J.C.…Christian B.T. Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. Brain. 2014;137(9):2556.
    1. Holland A.J., Hon J., Huppert F.A., Stevens F., Watson P. Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br. J. Psychiatry J. Ment. Sci. 1998;172:493–498.
    1. Holland A.J., Hon J., Huppert F.A., Stevens F. Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J. Intellect. Disabil. Res. 2000;44(2):138–146.
    1. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D.…DeKosky S.T. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(6):1630–1645.
    1. Iseri P.K., Altinaş Ö., Tokay T., Yüksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J. Neuroophthalmol. 2006;26(1):18–24.
    1. Iwatsubo T., Mann D.M.A., Odaka A., Suzuki N., Ihara Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann. Neurol. 1995;37(3):294–299.
    1. Jennings D., Seibyl J., Sabbagh M., Lai F., Hopkins W., Bullich S.…Marek K. Age dependence of brain β-amyloid deposition in Down syndrome an [18F]florbetaben PET study. Neurology. 2015;84(5):500–507.
    1. Johnson K.A., Schultz A., Betensky R.A., Becker J.A., Sepulcre J., Rentz D.…Sperling R. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 2015;79(1):110–119.
    1. Klunk W.E., Price J.C., Mathis C.A., Tsopelas N.D., Lopresti B.J., Ziolko S.K.…DeKosky S.T. Amyloid deposition begins in the striatum of Presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 2007;27(23):6174–6184.
    1. Landt J., D'Abrera J.C., Holland A.J., Aigbirhio F.I., Fryer T.D., Canales R.…Zaman S.H. Using positron emission tomography and carbon 11–labeled pittsburgh compound B to image brain fibrillar β-amyloid in adults with Down syndrome: safety, acceptability, and feasibility. Arch. Neurol. 2011;68(7):890–896.
    1. Lao P.J., Betthauser T.J., Hillmer A.T., Price J.C., Klunk W.E., Mihaila I.…Christian B.T. The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B. Alzheimers Dement. 2016;12(4):380–390.
    1. Lao P.J., Handen B.L., Betthauser T.J., Mihaila I., Hartley S.L., Cohen A.D.…Christian B.T. Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimers Dement. 2017;9:1.
    1. Lee N.R., Adeyemi E.I., Lin A., Clasen L.S., Lalonde F.M., Condon E.…Giedd J.N. Dissociations in Cortical morphometry in youth with Down syndrome: evidence for reduced surface area but increased thickness. Cereb. Cortex. 2016;26(7):2982–2990. New York, N.Y.: 1991.
    1. Lemere C.A., Blusztajn J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 1996;3(1):16–32.
    1. LeVine H., Spielmann H.P., Matveev S., Cauvi F.M., Murphy M.P., Beckett T.L.…Head E. Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan. Neurobiol. Aging. 2017;54:163–169.
    1. Lin A.-L., Powell D., Caban-Holt A., Jicha G., Robertson W., Gold B.T.…Head E. 1H-MRS metabolites in adults with Down syndrome: effects of dementia. NeuroImage. 2016;11:728.
    1. Liu F., Liang Z., Wegiel J., Hwang Y.-W., Iqbal K., Grundke-Iqbal I.…Gong C.-X. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008;22(9):3224–3233.
    1. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L.…Beach T.G. PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain. 2007;130(10):2607–2615.
    1. Mann D.M.A., Yates P.O., Marcyniuk B. Alzhiemer's dementia, presenile dementia, senile dementia of Alzheimer's type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol. Appl. Neurobiol. 1984;10(3):185–207.
    1. Margallo-Lana M.L., Moore P.B., Kay D.W.K., Perry R.H., Reid B.E., Berney T.P., Tyrer S.P. Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J. Intellect. Disabil. Res. 2007;51(6):463–477.
    1. Matthews D.C., Lukic A.S., Andrews R.D., Marendic B., Brewer J., Rissman R.A.…Rafii M.S. Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimers Dement. 2016;2(2):69.
    1. Medina D.A., Gaviria M. Diffusion tensor imaging investigations in Alzheimer's disease: the resurgence of white matter compromise in the cortical dysfunction of the aging brain. Neuropsychiatr. Dis. Treat. 2008;4(4):737–742.
    1. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 1997;42(1):85–94.
    1. Moncaster J.A., Pineda R., Moir R.D., Lu S., Burton M.A., Ghosh J.G.…Goldstein L.E. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One. 2010;5(5)
    1. Nelson D.L.D., Siddarth D.P., Kepe D.V., Scheibel M.K.E., Huang D.S.C., Barrio D.J.R., Small D.G.W. Positron emission tomography of brain β-amyloid and tau levels in adults with Down syndrome. Arch. Neurol. 2011;68(6):768.
    1. Newton R. Neuropsychiatry of Down syndrome. In: Newton Richard W., Puri Shiela, Marder Liz., editors. Down Syndrome: Current Perspectives. Mac Keith Press; 2015.
    1. Newton R., Puri S., Marder L. Mac Keith Press; 2015. Down Syndrome: Current Perspectives.
    1. d'Orsi G., Specchio L.M., Epilepsy, O. behalf of the A. S. G. on S. M Progressive myoclonus epilepsy in Down syndrome patients with dementia. J. Neurol. 2014;261(8):1584–1597.
    1. Powell D., Caban-Holt A., Jicha G., Robertson W., Davis R., Gold B.T.…Head E. Frontal white matter integrity in adults with Down syndrome with and without dementia. Neurobiol. Aging. 2014;35(7):1562–1569.
    1. Puri S., Morris J. Antenatal diagnosis: giving the news. In: Newton Richard W., Puri Shiela, Marder Liz., editors. Down Syndrome: Current Perspectives. Mac Keith Press; 2015.
    1. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010;362(4):329–344.
    1. Rafii M., Wishnek H., Brewer J., Donohue M., Ness S., Mobley W.…Rissman R. The Down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in Down syndrome. Front. Behav. Neurosci. 2015;9
    1. Rosen R.F., Ciliax B.J., Wingo T.S., Gearing M., Dooyema J., Lah J.J.…Walker L.C. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol. 2010;119(2):221.
    1. Sabbagh M., Edgin J. Clinical assessment of cognitive decline in adults with Down syndrome. Curr. Alzheimer Res. 2015;13(1):30–34.
    1. Sabbagh M.N., Fleisher A., Chen K., Rogers J., Berk C., Reiman E.…Beach T.G. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. Arch. Neurol. 2011;68(11):1461–1466.
    1. Sabbagh M.N., Chen K., Rogers J., Fleisher A.S., Liebsack C., Bandy D.…Reiman E.M. Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia. Alzheimers Dement. 2015;11(8):994–1004.
    1. Salem L.C., Sabers A., Kjaer T.W., Musaeus C., Nielsen M.N., Nielsen A.-G., Waldemar G. Quantitative electroencephalography as a diagnostic tool for Alzheimer's dementia in adults with Down syndrome. Dementia and Geriatric Cognitive Disorders Extra. 2015;5(3):404–413.
    1. Strydom A., Chan T., King M., Hassiotis A., Livingston G. Incidence of dementia in older adults with intellectual disabilities. Res. Dev. Disabil. 2013;34(6):1881–1885.
    1. Thal D.R., Rüb U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–1800.
    1. Tiano L., Busciglio J. Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q10? Biofactors. 2011;37(5):386–392.
    1. Wilcock D.M., Griffin W.S.T. Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J. Neuroinflammation. 2013;10(84)
    1. Wilson L. Doctoral Thesis. University of Cambridge; Cambridge, England: 2016. Brain connectivity in people with Down's syndrome: influences of atypical development and Alzheimer's disease neuropathology.
    1. Wilson L.R., Annus T., Zaman S., Holland A. Understanding the process: links between Down syndrome and dementia. In: Watchman Karen, Kingsley Jessica., editors. Intellectual Disability and Dementia: Research into Practice. 2014.
    1. Wolfe M.S. Tau mutations in neurodegenerative diseases. J. Biol. Chem. 2009;284(10):6021–6025.
    1. Yan Y., Wang C. Aβ40 protects non-toxic Aβ42 monomer from aggregation. J. Mol. Biol. 2007;369(4):909–916.
    1. Zigman W.B., Lott I.T. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment. Retard. Dev. Disabil. Res. Rev. 2007;13(3):237–246.
    1. Zotova E., Nicoll J.A., Kalaria R., Holmes C., Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res. Ther. 2010;2(1):1.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit